Effect of phenytoin on celecoxib pharmacokinetics in patients with glioblastoma

This publication has 62 references indexed in Scilit:

• Phase 1 study of erlotinib HCl alone and combined with temozolomide in patients with stable or recurrent malignant glioma1
  Neuro-Oncology, 2006
• Phase II Study of Imatinib Mesylate Plus Hydroxyurea in Adults With Recurrent Glioblastoma Multiforme
  Journal of Clinical Oncology, 2005
• Changes in gene expression contribute to cancer prevention by COX inhibitors
  Progress in Lipid Research, 2005
• Expression of cyclooxygenase-2 and epidermal growth factor receptor in primary and recurrent glioblastoma multiforme
  Zeitschrift für Krebsforschung und Klinische Onkologie, 2005
• COX-2: A Molecular Target for Colorectal Cancer Prevention
  Journal of Clinical Oncology, 2005
• Radiotherapy plus Concomitant and Adjuvant Temozolomide for Glioblastoma
  New England Journal of Medicine, 2005
• Increased endothelial uptake of paclitaxel as a potential mechanism for its antiangiogenic effects: Potentiation by Cox‐2 inhibition
  International Journal of Cancer, 2004
• Clinical Pharmacokinetics and Pharmacodynamics of Celecoxib
  Clinical Pharmacokinetics, 2000
• Common noncompartmental pharmacokinetic variables: are they normally or log-normally distributed?
  Journal of Biopharmaceutical Statistics, 1997
• Preparation of mean drug concentration-time curves in plasma. A study on the frequency distribution of pharmacokinetic parameters.
  CHEMICAL & PHARMACEUTICAL BULLETIN, 1985